Table 2.

Immunoreactivity of the cGMP TCMC-trastuzumab immunoconjugate.

Months	Competition			Immunoreactivity (% Bound)
				Specific	Non-Specific	Specific	Non-Specific	Adjusted % Bound
	GMP	Ref	ROB	GMP	GMP	Ref	Ref	GMP	Ref
0	18.0 a	20	ND b	73.1	4.8	72.8	3.0	68.3 c	69.8
3	3.0	3.2	ND	76.2	10.8	75.2	14.7	65.4	60.5
6	2.6	3.1	ND	57.8	12.6	67.5	11.4	45.2	56.1
12	1.2	2.9	2.9	62.2	6.4	59.9	3.2	55.8	56.7
18	1.5	3.0	3.0	75.1	1.5	64.4	0.9	73.6	63.5
24	2.5	8.0	8.0	76.3	2.4	74.6	0.8	73.9	73.8
26	2.0	6.0	2.0	63.4	ND	56.3	8.5	63.4	47.8
48	1.3	4.5	2.5	69.0	1.6	63.5	0.9	67.4	62.6
60	50.0	35.0	15.0	73.1	4.8	64.2	0.8	68.3	63.4

^a The values are the ng in 50 µL required for 50% inhibition of ¹²⁵I-trastuzumab reactivity with chimeric Erb2/Fc. ^b ND, not determined. ^c The adjusted % bound values are the % bound minus the % bound when 10 µg of trastuzumab is added to the wells along with the ²¹²Pb-labeled trastuzumab.